Literature DB >> 23774237

Characteristics of patients with advanced heart failure having eosinophilic infiltration of the myocardium in the recent era.

Saeko Yoshizawa1, Tomoko Sugiyama Kato, Donna Mancini, Charles C Marboe.   

Abstract

Eosinophilic infiltration of the myocardium is occasionally observed as an incidental histological finding in endomyocardial biopsy specimens before heart transplantation (HTx) as well as in explanted heart obtained at the time of HTx. However, the indications for HTx in these patients have not yet been fully established. We investigated the pre-HTx characteristics of the recipients with myocardial eosinophilic infiltration in the explanted heart and diagnosed as hypersensitivity myocarditis (HSM) (21 among 761 recipients, 2.8%). Dobutamine, a common cause of HSM, was administered to 12 patients (57%). Ten patients (47.6%) were on milrinone and 4 (19.0%) were on ventricular assist devices. Post-transplant survival of HSM patients was comparable to that of patients transplanted for active myocarditis or other cause of heart failure. In conclusion, myocardial eosinophilic infiltration is associated with multiple medications in patients with advanced heart failure; however, it does not affect the post-transplant prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774237     DOI: 10.1536/ihj.54.146

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  2 in total

1.  Case Report: Acute Eosinophilic Myocarditis With a Low-Flow Heart Failure With Preserved Ejection Fraction Phenotype.

Authors:  Hiroto Aota; Hiroyuki Yamamoto; Jun Isogai; Kyoko Imanaka-Yoshida; Michiaki Hiroe; Takahiro Tanaka
Journal:  Front Cardiovasc Med       Date:  2021-06-23

Review 2.  Current Diagnostic and Therapeutic Aspects of Eosinophilic Myocarditis.

Authors:  Petr Kuchynka; Tomas Palecek; Martin Masek; Vladimir Cerny; Lukas Lambert; Ivana Vitkova; Ales Linhart
Journal:  Biomed Res Int       Date:  2016-01-17       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.